共 123 条
[1]
Soda M(2007)Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer Nature 448 561-566
[2]
Choi YL(2004)Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2129-2139
[3]
Enomoto M(2004)EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 1497-1500
[4]
Lynch TJ(2009)Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 947-957
[5]
Bell DW(2011)Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS) J Clin Oncol 29 2866-2874
[6]
Sordella R(2010)Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial Lancet Oncol 11 121-128
[7]
Paez JG(2010)Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N Engl J Med 362 2380-2388
[8]
Janne PA(2011)Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Lancet Oncol 12 735-742
[9]
Lee JC(2012)Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial Lancet Oncol 13 239-246
[10]
Mok TS(2013)Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations J Clin Oncol 31 3327-3334